Microdosing For Migraines And Cluster Headaches: What The Research Shows And What I've Seen
- Anahita Anais
- Sep 3, 2021
- 7 min read
Updated: Jun 16
By Anahita Anais, Nervous System and Microdosing Expert and founder of Microdose Guru. This article is educational and is not medical advice. Always talk with your physician before changing how you treat a headache disorder.
Last reviewed: June 2026.
Cluster headache is one of the most severe pain conditions in medicine. Migraines are the most common, affecting roughly 12% of people in the United States, with billions of dollars in lost work and productivity tied to it every year. The indirect cost to employers alone is estimated at $19.3 billion annually (American Journal of Managed Care, 2021). For people who live with either condition, standard treatments do not always work, and the search for something better is real and urgent.
In recent years, a small but serious body of research has looked at whether psilocybin and LSD might help. The findings are early, and the evidence base is still thin, but it is no longer fringe. The work is being done at research hospitals, under controlled conditions, and published in peer-reviewed journals. Here is an honest account of what that research shows, where it falls short, and what I have observed in my own work.
The Research
Psilocybin (the active compound in certain mushrooms) and LSD belong to a family of molecules called tryptamines. That matters here because triptans, the most widely prescribed acute migraine drugs, share part of the same chemical backbone and act on serotonin receptors, as do these psychedelics (ACS Medicinal Chemistry Letters, 2022). This structural overlap is one reason researchers began asking whether psychedelics might affect headache disorders at all.
Cluster headache. The earliest signal came from a survey study. Sewell, Halpern, and Pope interviewed 53 people with cluster headache who had used psilocybin or LSD on their own, and many reported that the substances aborted attacks, ended cluster periods, or extended remission (Sewell et al., Neurology, 2006). A survey of self-selected users is a starting point, not proof, but it was enough to prompt controlled trials.
The first of those came out of the Yale-affiliated VA hospital in West Haven, Connecticut. In a randomized, double-blind, placebo-controlled trial, a low-dose psilocybin "pulse" regimen was tested in people with cluster headache. The overall result did not reach statistical significance, largely because the trial was small, but among those who received psilocybin, the data hinted at a meaningful reduction in attack burden for some participants (Schindler et al., Headache, 2022). A later blinded extension phase of that research, published in 2024, reported that a repeat psilocybin pulse reduced cluster attack frequency by roughly 50% in the period studied, and that whether someone responded the first time did not predict whether they responded to the repeat (Schindler et al., Journal of the Neurological Sciences, 2024). The researchers were careful to call these findings preliminary.
Migraine. The migraine picture has moved since this article was first written. An early exploratory study found that a single dose of psilocybin was associated with a reduction in migraine frequency over the two weeks measured, compared with placebo, and was well tolerated in a small sample (Schindler et al., Neurotherapeutics, 2021). The same group then ran a larger exploratory randomized controlled trial comparing single-dose and repeat-dose psilocybin against an active placebo. Published in Headache in late 2025, it followed 18 adults with at least two migraine days a week and tracked their headache diaries for weeks afterward. The one- and two-dose psilocybin groups saw roughly a 60% drop in migraine days, against about 40% in the placebo group (Schindler et al., Headache, 2025). The direction is encouraging, the placebo response was large, and the sample is still small. This is a signal, not a verdict.
Research has also begun reaching beyond migraine and cluster headache into rarer disorders. A 2024 open-label study tested low-dose psilocybin in people with short-lasting unilateral neuralgiform headache attacks (SUNHA), a notoriously treatment-resistant condition. Only three patients completed it, so it offered no firm clinical conclusion, though participants described a shifted relationship to their pain (Rucker et al., Headache, 2024). A 2025 review summarized the wider field as cautiously promising and far from settled (Current Neurology and Neuroscience Reports, 2025).
What the evidence does not yet show. It is worth being plain about the limits, because this is where a lot of online writing oversells.
The most important caveat is about dose. These trials did not test microdoses. The cluster headache study used about 0.143 mg/kg of psilocybin, and the migraine studies used single or repeated moderate doses. Those sit above the sub-perceptual microdose range. A canonical microdose of dried cubensis is about 0.05 to 0.30 g (50 to 300 mg), and an LSD microdose is roughly 5 to 20 µg. So the controlled research does not establish that microdosing specifically helps migraine or cluster headache. Microdosing for headache, as of now, rests mostly on anecdote, not trial data. (If you want a plain explanation of where the microdose line sits, see how much is a microdose.)
Beyond that, these are small studies. The cluster headache trial did not hit its primary endpoint, and the newest migraine trial showed a large placebo response. None of this establishes that psilocybin or LSD cures migraine or cluster headache, or that it reliably outperforms approved medications. Triptans relieve acute attacks but are not designed as preventives; some early research is exploring whether tryptamine psychedelics might have a more lasting effect, but that is a hypothesis under investigation, not a settled fact. Anyone who tells you the question is closed is ahead of the data.
On safety and legality. As of 2026, psilocybin and LSD remain Schedule I substances under U.S. federal law, unchanged since 1970, which makes unsupervised use both illegal in most places and unstudied at the doses people often try on their own. A 2026 federal executive order directed the FDA and DEA to speed up psychedelic research and clinical trials, but it did not legalize these substances or change their federal scheduling (McGuireWoods, 2026).
Two states, Oregon and Colorado, now run licensed psilocybin access programs, but those are tightly regulated and specific to those states (Oregon Health Authority). Most research participants report mild, short-lived side effects, but that is not the same as "risk-free."
Psychedelics can be genuinely unsafe for people with certain cardiovascular conditions, a personal or family history of psychosis, or those taking interacting medications. The harm-reduction point is simple: the lack of a clean diagnosis and a medical conversation is itself a risk. It is worth noting that dangerous practice is not limited to the underground: poorly run 'clinical' settings that skip proper screening carry real risk too. Rigor matters in both
For more on who should be cautious, see our two comprehensive harm-reduction guides below:
What I've Seen In My Work
The following is observation, not clinical evidence.
Headache is not usually why people come to me. They come to microdose for depression, anxiety, or to settle a dysregulated nervous system. But over the years, a handful of people I've worked with who also lived with migraines have mentioned, unprompted, that their headaches felt less frequent or less severe during a period of microdosing.
I hold these reports loosely. They are individual experiences, not measured outcomes. There's no headache diary, no placebo, no control. It's possible that calming a chronically activated nervous system plays some role in how often migraines show up for a given person, and that's a thread worth following. But I won't claim more than I can stand behind.
What I will say is this: the people who do best with microdosing are the ones who treat it as one part of an integrative approach, working with their doctor, not around them. The same pattern shows up across the chronic-pain reports I hear, which I've written about more fully in Microdosing For Chronic Pain. For a headache disorder especially, that integrative frame is not a nice-to-have. It's the whole point.
Frequently Asked Question
Does Microdosing Cure Migraines Or Cluster Headaches?
No. There is no evidence that microdosing cures either condition. The controlled trials that show promise used moderate, perceptible doses under medical supervision, not microdoses, and even those are small and preliminary. Anyone promising a cure is ahead of the science.
Is The Headache Research About Microdosing Specifically?
No. The published trials in migraine and cluster headache used larger doses given on a structured schedule, often called a "pulse" regimen. Whether sub-perceptual microdoses help headache disorders has not been tested in a controlled way. What exists for microdosing and headache is anecdote, not trial data.
How Is A Psychedelic Dose Different From A Microdose?
A microdose is sub-perceptual: small enough that you should not feel altered. For dried cubensis that's roughly 0.05 to 0.30 g, and for LSD roughly 5 to 20 µg. The headache trials used doses well above that range. If you want the full breakdown, see How Much Is A Microdose.
Is It Legal To Try This On My Own?
As of 2026, psilocybin and LSD remain Schedule I substances under U.S. federal law, so unsupervised use is illegal in most of the country. Oregon and Colorado run licensed, regulated psilocybin programs, but those are state-specific and tightly controlled. This is not something to navigate from internet instructions.
Can I Do This If I'm Already On Migraine Or Other Medications?
This is exactly the kind of question to bring to a physician, not to settle alone. Some medications interact with psychedelics, and headache disorders often involve daily or as-needed prescriptions. If you take a daily antidepressant, Can I Microdose If I'm Taking Antidepressants covers why that interaction matters.
Who Should Be Especially Cautious?
Anyone with certain cardiovascular conditions, a personal or family history of psychosis, or who takes interacting medications. The broader risk picture is covered in Can Microdosing Be Dangerous. A clean diagnosis and a real medical conversation are not optional steps.
The Honest Bottom Line
Early research suggests psilocybin and LSD may help reduce the frequency or severity of cluster headaches and migraines for some people, and the mechanism is plausible. But the studies are small and preliminary, the substances are illegal at the federal level and carry real risks, and none of this is a substitute for medical care. If you live with one of these conditions, the most useful step is an honest conversation with someone who knows your full history.
If you're weighing whether a careful, supervised approach makes sense for you, you can Book a Free Consultation with Microdose Guru to talk it through.
